Research
Hormonal
Myostatin (MSTN) co-localization with satellite cells decreases acutely following resistance exercise but returns to baseline levels after long-term resistance training, suggesting MSTN regulation occurs at the whole muscle level rather than specifically at the satellite cell level during chronic adaptation.
While acute exercise reduces the presence of the muscle growth inhibitor Myostatin on satellite cells, this effect does not persist after long-term training. This suggests that long-term muscle growth is not driven by chronic MSTN inhibition at the satellite cell level, but rather by other mechanisms like myonuclear addition.
GoodQualifiesHIGH confidence
Resistance training did not affect the proportion of SC positive for MSTN associated with either fibre type... This finding is in accordance with some reports which suggest that the inhibition of MSTN resulting in hypertrophy may be associated with changes in MSTN at the myofibre level and not the SC
Why this rating
Consistent with the main study design.
Source
The Acute Satellite Cell Response and Skeletal Muscle Hypertrophy following Resistance Training
Leeann M. Bellamy et al. · PLoS ONE · 2014
DOI 10.1371/journal.pone.0109739
rct · n=23Cited 150×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The magnitude of the acute satellite cell (SC) response to resistance exercise, specifically the expansion of type I fiber-associated SC between 24 and 72 hours post-exercise, positively correlates with the degree of skeletal muscle hypertrophy achieved following long-term resistance training.Good
- The expansion of the satellite cell pool associated with type II muscle fibers following long-term resistance training correlates with the degree of skeletal muscle hypertrophy.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →